Most commonly, the TKIs that target the BCR-ABL oncogenic pathways remain the frontline of CML therapy, which despite being effective initially, led to the later emergence of drug resistance. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.